Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

Nature Genetics

Volumn 48, Issue 9, 2016, Pages 1055-1059

  Zhou, Kaixin ^a   Yee, Sook Wah ^b   Seiser, Eric L ^c   Van Leeuwen, Nienke ^d   Tavendale, Roger ^a   Bennett, Amanda J ^e   Groves, Christopher J ^f   Coleman, Ruth L ^f   Van Der Heijden, Amber A ^g   Beulens, Joline W ^h   De Keyser, Catherine E ^j   Zaharenko, Linda ^i,k   Rotroff, Daniel M ^k,l   Out, Mattijs ^m,n   Jablonski, Kathleen A ^o,p   Chen, Ling ^q   Javorský, Martin ^q   Zidzik, Jozef ^q   Levin, Albert M ^r   Keoki Williams, L ^s   Dujic, Tanja ^t,u   Semiz, Sabina ^v,w   Kubo, Michiaki ^b   Chien, Huan Chieh ^x   Maeda, Shiro ^h,y   Witte, John S ^z   Wu, Longyang ^d,aa,ab   Tká, Ivan ^c,ac   Kooy, Adriaan ^ad   Van Schaik, Ron H N ^ae,af   Stehouwer, Coen D A ^af   Logie, Lisa ^ag   Sutherland, Calum ^e   Klovins, Janis ^e   Pirags, Valdis ^f   Hofman, Albert ^a   Stricker, Bruno H ^b   Motsinger Reif, Alison A ^e   Wagner, Michael J ^e   Innocenti, Federico ^e   Hart, Leen M ^f   Holman, Rury R ^e   McCarthy, Mark I ^a   Hedderson, Monique M ^e   Palmer, Colin N A ^e   Florez, Jose C ^e   Giacomini, Kathleen M ^f   Pearson, Ewan R ^a   more..

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of North Carolina   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Latvian Genome Data Base (LGDB)   (Latvia)

^j LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^k NORTH CAROLINA STATE UNIVERSITY   (United States)

^l Treant Zorggroep location Bethesda   (Netherlands)

^m Bethesda Diabetes Research Center   (Netherlands)

ⁿ GEORGE WASHINGTON UNIVERSITY   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p P J AFÁRIK UNIVERSITY   (Slovakia)

^q HENRY FORD HEALTH SYSTEM   (United States)

^r UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^s INTERNATIONAL UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^t RIKEN Center for Integrative Medical Sciences   (Japan)

^u UNIVERSITY OF THE RYUKYUS   (Japan)

^v UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x UNIVERSITY OF CALIFORNIA   (United States)

^y MAASTRICHT UNIVERSITY   (Netherlands)

^z UNIVERSITY OF LATVIA   (Latvia)

^aa PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^ab Inspectorate of Healthcare   (Netherlands)

^ac UNIVERSITY OF OXFORD   (United Kingdom)

^ad CHURCHILL HOSPITAL   (United Kingdom)

^ae DIVISION OF RESEARCH   (United States)

^af BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^ag HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC2A2 PROTEIN, HUMAN;

ADD ON THERAPY; ALLELE; ARTICLE; EUROPEAN; GENE EXPRESSION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE METABOLISM; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; ANALYSIS; BODY MASS; CAUCASIAN; DIABETES MELLITUS, TYPE 2; GENETICS; GLUCOSE BLOOD LEVEL; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE TRANSPORTER TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT, HERITABLE;

EID: 84981287483     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3632     Document Type: Article

References (51)

1. Madiraju, A.K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546 (2014).
2. DeFronzo, R.A. & Goodman, A.M. Effcacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333, 541-549 (1995).
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
4. Zhou, K. et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol. 2, 481-487 (2014).
5. Pawlyk, A.C., Giacomini, K.M., McKeon, C., Shuldiner, A.R. & Florez, J.C. Metformin pharmacogenomics: current status and future directions. Diabetes 63, 2590-2599 (2014).
6. Tkác, I. et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes. Metab. 15, 189-191 (2013).
7. Stocker, S.L. et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin. Pharmacol. Ther. 93, 186-194 (2013).
8. Jablonski, K.A. et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672-2681 (2010).
9. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273-280 (2008).
10. Zhou, K. et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58, 1434-1439 (2009).
11. van Leeuwen, N. et al. A gene variant near ATM is signifcantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of fve cohorts. Diabetologia 55, 1971-1977 (2012).
12. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2 & MAGIC investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120 (2011).
13. Zhou, K. et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87, 52-56 (2010).
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
15. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35, 731-737 (2012).
16. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677-1686 (2009).
17. Kahn, S.E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
18. Scott, R.A. et al. Large-scale association analyses identify new loci infuencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991-1005 (2012).
19. C levels via glycemic and nonglycemic pathways. Diabetes 59, 3229-3239 (2010).
20. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
21. van de Bunt, M. et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet. 11, e1005694 (2015).
22. Kabakchiev, B. & Silverberg, M.S. Expression quantitative trait loci analysis identifes associations between genotype and gene expression in human intestine. Gastroenterology 144, 1488-496 (2013).
23. Manz, F. et al. Fanconi-Bickel syndrome. Pediatr. Nephrol. 1, 509-518 (1987).
24. Fanconi, G. & Bickel, H. Chronic aminoaciduria (amino acid diabetes or nephrotic-glucosuric dwarfsm) in glycogen storage and cystine disease. Helv. Paediatr. Acta 4, 359-396 (1949).
25. Miller, R.A. et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256-260 (2013).
26. Hosokawa, M. & Thorens, B. Glucose release from GLUT2-null hepatocytes: characterization of a major and a minor pathway. Am. J. Physiol. Endocrinol. Metab. 282, E794-E801 (2002).
27. Burcelin, R., Dolci, W. & Thorens, B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 49, 1643-1648 (2000).
28. Seyer, P. et al. Hepatic glucose sensing is required to preserve β cell glucose competence. J. Clin. Invest. 123, 1662-1676 (2013).
29. Hundal, R.S. et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49, 2063-2069 (2000).
30. Fullerton, M.D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649-1654 (2013).
31. Pau, C.T., Keefe, C., Duran, J. & Welt, C.K. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J. Clin. Endocrinol. Metab. 99, 1870-1878 (2014).
32. McCreight, L.J., Bailey, C.J. & Pearson, E.R. Metformin and the gastrointestinal tract. Diabetologia 59, 426-435 (2016).
33. Ait-Omar, A. et al. GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes 60, 2598-2607 (2011).
34. Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B. & Klein, T.E. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 22, 820-827 (2012).
35. Bailey, C.J. The current drug treatment landscape for diabetes and perspectives for the future. Clin. Pharmacol. Ther. 98, 170-184 (2015).
36. Banda, Y. et al. Characterizing race/ethnicity and genetic ancestry for 100, 000 subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Genetics 200, 1285-1295 (2015).
37. Morris, A.P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981-990 (2012).
38. Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616-625 (2009).
39. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
40. Price, A.L. et al. Principal components analysis corrects for stratifcation in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
41. Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J.E. & Gerstein, H.C. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33, 1859-1864 (2010).
42. Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat. Commun. 5, 5068 (2014).
43. Mägi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 11, 288 (2010).
44. Howie, B.N., Donnelly, P. & Marchini, J. A fexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
45. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
46. Innocenti, F. et al. Identifcation, replication, and functional fne-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7, e1002078 (2011).
47. Schröder, A. et al. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J. 13, 12-20 (2013).
48. Schadt, E.E. et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107 (2008).
49. Xia, K. et al. seeQTL: a searchable database for human eQTLs. Bioinformatics 28, 451-452 (2012).
50. Dahlin, A. et al. Gene expression profling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol. Pharm. 10, 650-663 (2013).
51. Liang, X. et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). Mol. Pharm. 12, 4301-4310 (2015).